Amy R. Pettit, PhD

Articles

March 17th 2017

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"

Jalpa A. Doshi, PhD Pengxiang Li, PhD Amy R. Pettit, PhD J. Samantha Dougherty, PhD Ashley Flint, MPP Vrushabh P. Ladage, BS

Medicare claims analyses offer insight into how proposed policy changes would affect out-of-pocket prescription costs for Part D beneficiaries requiring specialty drugs.

March 18th 2016

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

Jalpa A. Doshi, PhD Pengxiang Li, PhD Hairong Huo, PhD, MS Amy R. Pettit, PhD Rishab Kumar Brendan M. Weiss, MD Scott F. Huntington, MD, MPH

A Medicare claims analysis of patients newly diagnosed with chronic myeloid leukemia revealed that high cost sharing was associated with reduced and/or delayed tyrosine kinase inhibitor initiation under Part D.

March 17th 2016

Impact of Cost Sharing on Specialty Drug Utilization and Outcomes: A Review of the Evidence and Future Directions

Jalpa A. Doshi, PhD Pengxiang Li, PhD Vrushabh P. Ladage, BS Amy R. Pettit, PhD Erin A. Taylor, PhD, MSPH

The authors review published evidence regarding associations between high cost sharing for specialty pharmaceuticals indicated for rheumatoid arthritis, multiple sclerosis, and cancer, and their utilization.